In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...
Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...
A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?
The medications are so common now, two-thirds of the clinic’s calls for insurance pre-authorizations are for the big three: ...
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
In 2024, new medicines changed how we think about healthy weight loss—but psychological factors remain just as important as ...
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
This time last year, people were still bickering about whether Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound represented a shortcut to losing weight or a medical breakthrough.
The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment ... Novo Nordisk's GLP-1 drugs Ozempic and Wegovy, this class of medications has become ...
On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss ... Could Ozempic and Wegovy come off the shortage list? The FDA said Novo ...
Pennsylvania Medicaid insurers spent nearly $300 million on Wegovy, Zepbound, and other new anti-obesity drugs in the year that ended Oct. 31, according to a new analysis from Real Chemistry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback